Gene therapy aims to fix immune system in rare disease

NCT ID NCT06876363

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a one-time gene therapy called EN-374 for people with X-linked chronic granulomatous disease (X-CGD), a rare immune disorder that causes severe infections. The treatment uses a modified virus to deliver a working gene to blood stem cells, aiming to restore the ability of white blood cells to kill germs. The study will enroll about 15 males aged 3 months and older, and will check safety and whether the therapy increases functional immune cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for X-LINKED CHRONIC GRANULOMATOUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Boston Children's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Columbia University Irving Medical Center, Morgan Stanley Children's Hospital

    RECRUITING

    New York, New York, 10032, United States

  • Duke University

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Johns Hopkins All Children's Hospital

    RECRUITING

    St. Petersburg, Florida, 33701, United States

  • University College London Hospital

    RECRUITING

    London, NW1 2PG, United Kingdom

  • University of California, Los Angeles

    RECRUITING

    Los Angeles, California, 90095, United States

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94158, United States

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55454, United States

  • University of Utah, Primary Children's Hospital

    RECRUITING

    Salt Lake City, Utah, 84113, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.